38 results about "Bacterial vaginitis" patented technology

The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.

The invention relates to the field of pharmacy, and discloses a Chinese herbal medicine and marine extract combined antibacterial and anti-inflammatory pharmaceutical composition which comprises the following components in parts by weight: 5-10 parts of baicalin extract; 3 to 7 parts of an andrographolide extract; 2-5 parts of sulfated brown algae polysaccharide; 0.2 to 1 part of sponge extract; wherein the baicalin extract is derived from roots of scutellaria baicalensis and is obtained by extracting with an ethanol-water mixed solvent; the andrographolide extract is derived from the whole herb of andrographis paniculata and is obtained by extracting with an ethanol-water mixed solvent; the sulfated fucoidan is derived from fucoidan and is prepared by enzymolysis and alcohol precipitation methods; the sponge extract is derived from sponge and is obtained by organic solvent extraction, separation and purification. By adopting the technical scheme of synergistically compounding the Chinese herbal medicine active ingredients and the marine extract, the technical effects of destroying a biological membrane barrier and removing stubborn infection lesions in treatment of bacterial vaginitis, candida vaginitis associated biological membrane infection and cervicitis are achieved.

Provided is a Lactobacillus crispatus VB250, which is deposited in the China General Microbiological Culture Collection Center (CGMCC) on 20 February 2023, with the deposit number of CGMCC No.26574. The Lactobacillus crispatus provided in the present invention has good growth activity and multiple pathogenic bacteria inhibition activity in a low pH environment, and can be used for preventing and / or relieving and / or treating related diseases caused by vaginal flora disorder, such as bacterial vaginitis, colpitis mycotica, trichomonas vaginitis, aerobic vaginitis, senile vaginitis, and vaginitis caused by virus infection. Moreover, the Lactobacillus crispatus has great application prospects in preparation of products such as food, health-care food, drugs, and hygienic products.

Described herein are compositions for treatment of vaginal dysbiosis (e.g., bacterial vaginosis), symptoms of vaginal dysbiosis (e.g., bacterial vaginosis), or conditions / disorders associated with vaginal dysbiosis (e.g., bacterial vaginosis). Also disclosed herein are methods for treating vaginal dysbiosis (e.g., bacterial vaginosis) in an individual in need thereof, methods for reducing the risk of vaginal dysbiosis (e.g., bacterial vaginosis) in an individual in need thereof, methods for preventing recurrence of vaginal dysbiosis (e.g., bacterial vaginosis) in an individual treated for a prior episode of vaginal dysbiosis (e.g., bacterial vaginosis). Also described are methods for restoring Lactobacillus dominated microbiota, including L. crispatus-dominated microbiota or microbiota dominated by other non-iners Lactobacillus species, in an individual in need thereof.

The invention relates to an external traditional Chinese medicine preparation for preventing and treating HPV (human papillomavirus) infection, which belongs to the technical field of external medicines and comprises the following raw materials: 1-10 parts of gallnut, 1-10 parts of szechwan chinaberry fruit, 1-10 parts of golden cypress, 1-10 parts of fructus cnidii, 1-10 parts of radix sophorae flavescentis, 1-10 parts of cyrtomium rhizome, 1-10 parts of rhizoma atractylodis, 1-10 parts of cortex dictamni, 0-10 parts of calomel, 0-10 parts of cinnabar and 0-10 parts of borneol. The external traditional Chinese medicine preparation disclosed by the invention is locally administrated through the vagina, so that the active ingredients directly reach the focus, and the external traditional Chinese medicine preparation is safe and convenient, and is suitable for resisting HPV infection, cervicitis, cervical erosion, pelvic inflammation, bacterial vaginitis, trichomonas vaginitis, mixed vaginitis, peculiar smell of private parts, pruritus of private parts, dryness of private parts, abnormal leucorrhea and pruritus and causalgia of vulva.

The present application relates to the field of pharmacy, disclose the medicine composition for antibacterial and anti-inflammatory of Chinese herbal medicine and marine extract combination, including: baicalin extract 5~10 parts; andrographolide extract 3~7 parts; sulfated fucoidan 2~5 parts; spongin extract 0.2~1 part; wherein: baicalin extract is derived from the root of scrophulariaceae, is extracted by ethanol-water mixed solvent; andrographolide extract is derived from the whole plant of andrographis, is extracted by ethanol-water mixed solvent; sulfated fucoidan is derived from brown algae, is prepared by enzymolysis and alcohol precipitation method; spongin extract is derived from sponges, is extracted and separated and purified by organic solvent. Through the technical scheme of the synergistic combination of active ingredients of Chinese herbal medicine and marine extract, the technical effect of destroying the biofilm barrier and clearing the stubborn infection focus in the treatment of bacterial vaginitis, candida vaginitis and cervical inflammation associated with biofilm infection is achieved.

The present invention is related to deuterated secnidazole, a prodrug thereof, a hydrate thereof, a solvate thereof, a polymorph thereof, or a pharmaceutically acceptable salt thereof and its use for the treatment of bacterial vaginosis or trichomoniasis in a subject in need thereof. The present invention is also related to pharmaceutical compositions and methods and uses of treating bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, or a combination thereof.

The invention provides a vaginal flora repairing liquid and a preparation method thereof. Specifically, the repair liquid prepared from the lactobacillus paracasei CGMCC No. 1.12731, the lactobacillus rhamnosus CGMCC 24282 and the lactobacillus gasseri CGMCC No. 22909 in a specific mass ratio can be used for well killing pathogenic bacteria, has no obvious toxic or side effect and is low in cost. The broad-spectrum vaginitis bactericidal peptide YDG-C screened by the invention is further added into the repair liquid, so that the treatment effect on bacterial vaginitis can be further improved. The preparation method is simple, low in cost and suitable for large-scale popularization and application.

The present invention relates to a composition, which contains lactobacillus and lactobacillus, wherein the number of viable lactobacillus in the composition is not less than 1×10 6 CFU, the composition contains 1×10 6 ~1×10 10 The composition of the present invention can be used to treat and / or prevent vaginal infections such as bacterial vaginosis and aerobic bacterial vaginitis, and can be used in the pharmaceutical field.

The invention belongs to the technical field of medical gel, and particularly relates to gynecological antibacterial gel and a preparation method thereof. The gel comprises an antibacterial phase and a bacterium promoting phase, and broad-spectrum inhibition of common pathogenic bacteria is achieved through the synergistic proportion of naringin, nisin and ethyl lauroyl arginate hydrochloride; meanwhile, a lactobacillus rhamnosus metabolite, sodium hyaluronate and the like are introduced to construct a bacterium promoting phase, and probiotic colonization and vagina micro-ecological balance reconstruction are promoted. The pH value of the gel is stabilized at 4.0-4.5, and the gel has good rheological properties and retention performance. In the preparation method, all the components are added step by step, the system temperature and stirring conditions are controlled, and the component activity and the product stability are guaranteed. The traditional Chinese medicine composition can effectively relieve bacterial vaginitis, fungal infection and micro-ecological disorder, and has a synergistic, safe and mild comprehensive nursing effect.

The invention relates to the technical field of gene detection, in particular to a primer group and application thereof, and a training method of a bacterial vaginitis diagnosis model. The primer group is used for diagnosing bacterial vaginitis and comprises a specific primer, and the target areas are used for specifically amplifying the following target pathogens: Atortobacterium vaginalis, Gardneria vaginalis, type 1 giant coccus, type 2 giant coccus, bacterial vaginitis related bacteria 2, campylobacter kirschengensis, campylobacter pudicus, two-way prevotella, Lactobacillus crispatus, Lactobacillus inervis, Lactobacillus gasseri and Lactobacillus jensenii. The invention also provides application of the primer group and a training method of a bacterial vaginitis diagnosis model. The primer group can be used for carrying out high-throughput sequencing on a to-be-detected sample, 12 target pathogens can be detected at the same time, a bacterial vaginitis diagnosis model is further constructed, and the primer group can be used for clinical diagnosis of bacterial vaginitis and has good specificity and sensitivity.

The invention provides a co-loaded drug liposome composite gel containing anti-inflammatory polypeptide as well as a preparation method and application thereof, and belongs to the technical field of medicines. The amino acid sequence of the anti-inflammatory polypeptide disclosed by the invention is as shown in SEQ ID NO. 1. According to the invention, hydrophobic beta-eudesmol and atractydin are entrapped in liposome, then the liposome, berberine, fructo-oligosaccharide, anti-inflammatory polypeptide and Pluronic F-127 are prepared into composite gel, and the composite gel is jointly delivered to an action site to achieve a synergistic interaction effect. The beta-eudesmol enhances the planting capacity of the lactobacillus; atractylodin promotes the expression of tight junction protein and enhances the protection function of the vaginal epithelial barrier; through the synergistic effect of the anti-inflammatory polypeptide and the traditional Chinese medicine monomer, the repairing effect on mucosa can be accelerated; berberine inhibits growth of pathogenic bacteria, fructo-oligosaccharide promotes proliferation of beneficial bacteria, and vaginal microecological balance is further adjusted. The traditional Chinese medicine composition has a good treatment effect on aerobic bacterial vaginitis and has a good market application prospect.

The utility model discloses a bacterial vaginitis detection device, which relates to the technical field of vagina detection, and comprises a folding comparison component and a folding detection component, the folding comparison component and the folding detection component are oppositely arranged in a folding manner, the positive end of the folding comparison component is provided with a result comparison display unit, and the negative end of the folding detection component is provided with a result display unit. When the folding type comparison component and the folding type detection component are folded in half, a detection area of the collecting and sampling unit and a hole in the middle of the result comparison display unit are arranged on the same plane in an attached mode, a test result can be accurately known in the use process, operation is easy to operate, and the test efficiency is improved. The diagnosis time of the bacterial vaginitis is shortened, and the use is more convenient. The cost and the cost performance are greatly reduced, the integrated design is more environment-friendly, the device is small and portable and is easy to carry about, and the user experience and the diagnosis efficiency are improved by simplifying the operation process and improving the result accuracy.

The invention discloses a lactobacillus crispatus MYT-LC01 and an application of the lactobacillus crispatus MYT-LC01. The preservation number of the Lactobacillus crispatus MYT-LC01 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) NO: 32209, and the preservation number of the Lactobacillus crispatus MYT-LC01 provided by the invention is CGMCC NO: 32209. The 16S rDNA (ribosomal deoxyribonucleic acid) sequence of the lactobacillus crispatus MYT-LC01 is as shown in SEQ ID NO: 1. The lactobacillus crispatus MYT-LC01 has an antagonistic effect on vagina-related harmful bacteria (candida albicans, staphylococcus aureus and escherichia coli), and can be used for inhibiting the occurrence of vulvovaginal candidiasis, vulvofolliculitis, bacterial vaginitis, cervicitis and urinary tract infection.

The present invention is related to deuterated secnidazole, a prodrug thereof, a hydrate thereof, a solvate thereof, a polymorph thereof, or a pharmaceutically acceptable salt thereof and its use for the treatment of bacterial vaginosis or trichomoniasis in a subject in need thereof. The present invention is also related to pharmaceutical compositions and methods and uses of treating bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, or a combination thereof.

The application discloses a traditional Chinese medicine composition for treating vaginitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises 12 Chinese herbal medicines, i.e. Sophora flavescens, Phellodendron chinense, Dictamnus dasycarpus, Herba Artemisiae Scopariae, Herba Taraxaci, Chrysanthemum indicum, Herba Portulacae, Cnidium monnieri, Angelica polymorpha, Herba Verbena, Herba Menthae and Saposhnikovia divaricata, and further comprises Salix viminalis, Eucalyptus, Ephedra sinica, anthocyanin quaternary ammonium salt, Ocimum basilicum, Houttuynia cordata, polysialic acid, polydopamine, antibacterial polypeptide modified chitosan hydrochloride and artemether. The traditional Chinese medicine composition is prepared by mixing traditional Chinese medicines and bactericidal and bacteriostatic biocompatible materials to prepare various medicaments. The traditional Chinese medicine composition is used for treating pruritus and leukorrhagia caused by endogenous insect poison and burning of yin fluid, and is used for treating bacterial vaginitis, mycotic vaginitis, trichomonal vaginitis and vulvitis. In clinical tests, the traditional Chinese medicine composition has remarkable treatment effect, and the cure rate is more than 95%.

The invention provides bacteriostatic gel for women and a preparation method thereof, and belongs to the technical field of gynecological gel. The gel comprises 97%-99% of a multi-layer structure base material and 1%-3% of a natural plant effective component. The effective components comprise seven natural components such as a fructus cnidii extract, a helichthys italica extract and a radix sophorae flavescentis extract, and the base material comprises multiple layers of hydrogel. In the use process of the bacteriostatic gel for women, the fructus cnidii extract and the radix sophorae flavescentis extract can directly kill pathogenic bacteria of bacterial vaginitis and have an inhibition effect on HPV viruses, and the tea leaf extract and the psidium guajava leaf extract have antioxidant and bacteriostatic characteristics, so that the capacity of removing harmful microorganisms can be further enhanced. And the base material comprising multiple layers of hydrogel not only can enable bacteriostatic and anti-inflammatory components to continuously act on a focus part and improve the treatment effect on vaginitis and vulvitis, but also can reduce direct stimulation of subsequent effective components on sensitive mucous membranes, and is especially suitable for mucous membrane fragile scenes such as gynecologic operations and acute inflammation stages.

The present invention relates to a Lactobacillus acidophilus SY23 for preventing and treating bacterial vaginitis and application thereof. The Lactobacillus acidophilus SY23 is classified and named as Lactobacillus acidophilus. Lactobacillus acidophilus , the deposit number is CGMCC No. 30465, and the deposit date is April 28, 2024. The postbiotic strain has an inhibitory effect on the pathogenic bacteria related to bacterial vaginitis, can reduce the level of inflammatory factors in vaginal tissue, and increase the level of immunoglobulins, and has excellent efficacy in preventing and treating bacterial vaginitis.

The present invention relates to a pharmaceutical composition or a composition for a medical device or a composition for a food supplement (briefly, the composition (s) of the present invention) based on lactic acid bacteria belonging to the species Lactobacillus fermentum for vaginal and oral use for the simultaneous treatment of vaginal infections, disorders or diseases of fungal and bacterial origin. Specifically, the present invention relates to a said composition comprising pharmaceutical- and / or food-grade excipients and a mixture, which comprises or, alternatively, consists of at least a strain of bacteria belonging to the species Lactobacillus fermentum for vaginal and oral use for the simultaneous treatment of vaginal infections, disorders or diseases selected from candidiasis, vaginitis, vulvovaginitis or bacterial vaginosis.

To provide an inhibitor of bacterial vaginosis.SOLUTION: An inhibitor of bacterial vaginosis comprises lactic acid and / or a salt thereof.SELECTED DRAWING: None

The invention provides a novel application of an antibacterial peptide Ly (PEG)-1 reported at an earlier stage in vaginitis, belongs to the technical field of biomedical polypeptides, and particularly relates to preparation of the antibacterial peptide Ly (PEG)-1, an effect of the antibacterial peptide Ly (PEG)-1 on main vaginal pathogenic bacteria and symbiotic bacteria and an application of the antibacterial peptide Ly (PEG)-1 in prevention or treatment of bacterial vaginitis. The antibacterial peptide Ly (PEG)-1 provided by the invention is short in sequence, low in production cost, capable of strongly inhibiting main pathogenic bacteria of vagina, small in influence on main normal bacteria of the main pathogenic bacteria, capable of effectively treating vagina inflammation and maintaining the steady state of vaginal flora, high in stability and good in antibacterial effect. Vagina inflammatory diseases caused by infection of various pathogenic bacteria can be prevented and treated through various administration modes such as spraying, instillation, suppositories and effervescent tablets or systemic administration modes such as intraperitoneal injection and the like.

The application discloses a vaginal probiotic composition for relieving multiple vaginitis, and belongs to the technical field of microorganisms. The combination of Lactobacillus crispatus CCFM1298, Lactobacillus gasseri CCFM1201 and fructooligosaccharide is selected based on the growth characteristics of the strains, the synergistic symbiosis of the combined strains is realized, and the effect of multiple relief of vaginitis is realized. The probiotic composition can relieve vaginal tissue inflammation, regulate the local immune system of the vagina, and help relieve and improve bacterial vaginitis and candidal vaginitis of women. Moreover, since the probiotics are all derived from the vagina of healthy women, the probiotics are used in the preparation of products and sanitary products for female vaginitis, help relieve and improve female vaginitis, and have a good application prospect.

A controlled release, antimicrobial gel for the treatment of vaginal infections, comprises a muco-adhesive gel matrix containing one or more anti-infective agents bound to said matrix and effective for the treatment of vaginal infections and capable of pH dependent delivery of said one or more anti-infective agents as a single application to the vaginal cavity over a period of 3 days, while the muco-adhesive gel matrix remains bound to the vaginal epithelia. The preferred anti-infective agents are thymol and carvacrol in combination. The antimicrobial gel is biocidal against biofilms formed by the causative agents of bacterial vaginosis, trichomoniasis and candidiasis. The antimicrobial gel is effective for achieving sustained delivery of the anti-infective agents to the vaginal cavity at a therapeutically efficacious dose from a single application of the gel for the treatment and prevention, and prevention of recurrence, of bacterial vaginosis, trichomoniasis and candidiasis.

The invention relates to the field of female genital tract microbial flora typing, and discloses a method for typing female genital tract microbial flora by applying a microbial flora ecological index and an artificial intelligence technology. Ecological indexes comprise a diversity index, a dominance index (community dominance and species dominance) and species abundance, and female genital tract microbial florae are divided into simple florae and complex florae according to an ecological index clustering result. An artificial intelligence model is trained and validated using the typing results, and the artificial intelligence model can be used for typing the microbial flora of the female genital tract so as to continuously optimize the artificial intelligence model. Due to the fact that pathogenic mechanisms of different types of microbial florae may be different, the method and technology provided by the invention contribute to personalized diagnosis and treatment of bacterial vaginitis. The method is not only suitable for female genital tract microbial flora typing, but also can be used for typing microbial flora of human intestinal tracts, oral cavities, skin, reproductive systems, lungs, breast milk, secretions and the like.

The present invention discloses the application of Lactobacillus iners in evaluating the prognosis of bacterial vaginosis. The present invention provides the application of the relative abundance of Lactobacillus iners in the vagina as a marker in the preparation of a product for evaluating the prognosis of bacterial vaginosis. The present invention has found that the prognosis of bacterial vaginosis patients with a higher relative abundance of Lactobacillus iners in the vagina before treatment is significantly better than that of bacterial vaginosis patients with a lower relative abundance of Lactobacillus iners in the vagina before treatment after conventional metronidazole treatment. The present invention is of great significance for further refinement of diagnosis and treatment of bacterial vaginosis.

The traditional Chinese medicine gel vaginal plug is prepared from the following raw materials in parts by weight: 6-8 parts of channel-warming and cold-dispelling traditional Chinese medicines, 4-5 parts of fresh ginger, 3-4 parts of cinnamon, 2-3 parts of fructus evodiae and 3-4 parts of rhizoma cyperi. 6-7 parts of antibacterial and anti-inflammatory traditional Chinese medicines, 6-7 parts of radix sophorae flavescentis and 6-7 parts of fructus cnidii; 4-5 parts of salvia miltiorrhiza and 3-4 parts of safflower carthamus; the gel matrix comprises the following components in parts by weight: 1.7 to 1.9 parts of carbomer 940, 0.7 to 0.9 part of chitosan and 0.4 to 0.5 part of sodium hyaluronate; the auxiliary materials comprise 0.15 to 0.18 part of azone serving as a transdermal enhancer and 0.07 to 0.09 part of phenoxyethanol serving as a preservative. Through vaginal administration, the uterine cavity environment can be improved, the temperature of the body and the small intestine can be increased in cooperation with online body temperature regulation guidance, gynecological problems such as mycotic and bacterial vaginitis, cervical erosion, polyp, HPV infection, cyst and myoma can be improved in an auxiliary mode, cyst and myoma improvement is relatively slow, use is convenient, and safety is high.

The invention provides a probiotic composition containing lactobacillus gasseri LN32 and lactobacillus crispatus LN70 and application of the probiotic composition to reduction of vaginal infection risk, and belongs to the technical field of microorganism application. The probiotic feed additive contains four strains of probiotics, including plant lactobacillus LN66, lactobacillus rhamnosus LN56, lactobacillus gasseri LN32 and lactobacillus crispatus LN70. The probiotic composition realizes vaginal flora reconstruction through oral administration, inhibits reproduction of Gardneria vaginalis and Candida albicans, increases lactobacillus colonization, and eliminates abnormal leucorrhea, vaginal scorching heat and itching, frequent urination, urgent urination, dysuria and the like. The probiotic composition is combined with a conventional carrier, and is applied to preparation of food, dietary supplement or medicine for preventing and / or treating microecological imbalance of vagina and urethra, bacterial vaginitis, colpitis mycotica and urethral infection. Therefore, vaginal harmful bacteria are inhibited, vaginal flora is reconstructed, and the vaginal infection risk and the urethral infection risk are reduced.

The present invention provides a co-loaded drug liposome composite gel containing an anti-inflammatory polypeptide, and a preparation method and application thereof, and belongs to the field of medical technology. The amino acid sequence of the anti-inflammatory polypeptide of the present invention is shown in SEQ ID NO.1. The present invention encapsulates hydrophobic β-eucalyptol and atractylodesin in liposomes, and then prepares a composite gel with liposomes, berberine, oligofructose, anti-inflammatory polypeptide, and Pluronic F-127, and delivers them to the site of action together to achieve a synergistic effect. β-eucalyptol enhances the colonization ability of lactobacillus; atractylodesin promotes the expression of tight junction proteins and enhances the protective function of the vaginal epithelial barrier; the synergistic effect of anti-inflammatory polypeptides and traditional Chinese medicine monomers can accelerate the repair effect on the mucosa; berberine inhibits the growth of pathogens, and oligofructose promotes the proliferation of beneficial bacteria, further regulating the balance of vaginal microecology. The present invention has a good therapeutic effect on aerobic bacterial vaginitis and has a good market application prospect.

The present application provides a kind of lactobacillus gasseri LN32 and lactobacillus crispatus LN70 containing probiotic composition and application in reducing the risk of vaginal infection, belong to microbial application technical field.Containing 4 strains of probiotics, including lactobacillus plantarum LN66, lactobacillus rhamnosus LN56, lactobacillus gasseri LN32 and lactobacillus crispatus LN70.The probiotic composition is realized by oral route, vaginal flora reconstruction, inhibit the reproduction of gardnerella vaginalis and candida albicans, increase lactobacillus colonization, eliminate abnormal leucorrhea, vaginal burning and itching, frequent urination, urgency and pain.The probiotic composition is combined with conventional carrier, applied to prepare food, dietary supplement or drug for preventing and / or treating vaginal and urethral microecological disorder, bacterial vaginitis, mycotic vaginitis and urethral infection, and then the present application realizes inhibiting harmful bacteria in vagina, reconstructing vaginal flora to reduce the risk of vaginal infection and reduce the risk of urethral infection.

Methods and compositions for detection of vulvovaginal candidiasis (VVC), trichomoniasis and bacterial vaginosis (BV) are disclosed herein. In some embodiments, the presence or absence of WC-associated Candida, Trichomonas vaginalis, and a plurality of BV-related bacteria in a sample is determined using multiplex nucleic acid-based testing methods.